Nalaganje...
Molecular Modeling of ALK L1198F and/or G1202R Mutations to Determine Differential Crizotinib Sensitivity
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase that has been recognized as a therapeutic target for EML4-ALK fusion-positive nonsmall cell lung cancer (NSCLC) treatment using type I kinase inhibitors such as crizotinib to take over the ATP binding site. According to Shaw’s measuremen...
Shranjeno v:
| izdano v: | Sci Rep |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Nature Publishing Group UK
2019
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6684801/ https://ncbi.nlm.nih.gov/pubmed/31388026 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-019-46825-1 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|